Serum Soluble Vascular Endothelial Growth Factor Receptor 1 as a Potential Biomarker of Hepatopulmonary Syndrome

Li, Yu-jie; Wu, Xian-Feng; Wang, Dan-Dan; Li, Peng; Liang, Hao; Hu, Xiao-Yan; Gan, Jia-Qi; Sun, Yi-Zhu; Li, Jun-Hong; Li, Jun; Shu, Xin; Song, Ai-Lin; Yang, Chun-Yong; Yang, Zhi-Yong; Yu, Weifeng; Yang, Li‐Qun; Wang, Xiaobo; Belguise, Karine; Xia, Zhengyuan; Yi, Bin

doi:10.14218/jcth.2022.00421

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pathological angiogenesis has recently been recognized as a vital mechanism underlying HPS. 11 , 23 However, the first RCT focused on anti-angiogenic therapy did not significantly improve hypoxemia and negatively impacted the quality of life. 12 Interestingly, HPS almost invariably resolves following liver transplantation, highlighting that alleviating liver injury should be a primary treatment goal for HPS.…”

Section: Discussionmentioning

confidence: 99%

The Therapeutic Effects of Baicalein on the Hepatopulmonary Syndrome in the Rat Model of Chronic Common Bile Duct Ligation

Zeng,

Lei,

Yang

et al. 2024

J Clin Transl Hepatol

Self Cite

View full text Add to dashboard Cite

Background and Aims Hepatopulmonary syndrome (HPS) is characterized by arterial oxygenation defects due to pulmonary vascular dilation in liver disease. To date, liver transplantation remains the only effective treatment for HPS. This study aimed to explore the preventative role of baicalein in HPS development. Methods Sixty male rats were randomly assigned to three groups: sham, common bile duct ligation (CBDL), and baicalein, receiving intraperitoneal injections of baicalein (40 mg·kg −1 ·d −1 , diluted in saline) for 21 days. Survival rate, liver and kidney function, and bile acid metabolism levels were evaluated. Liver and lung angiogenesis and hepatic glycogen staining were assessed, and the expression of relevant proteins was evaluated by immunohistochemistry. Results Baicalein improved survival rates and hypoxemia in rats post-CBDL, reducing angiogenic protein levels and enhancing glucose homeostasis. Compared to the untreated group, baicalein suppressed the expression of vascular endothelial growth factor, placental growth factors, matrix metalloprotease 9 and C-X-C motif chemokine 2, and it increased the expression of glycemic regulatory proteins, including dipeptidyl peptidase-4, sirtuin 1, peroxisome proliferator-activated receptor gamma co-activator 1α, and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3. Conclusion Baicalein significantly improves hepatic function and hypoxia in HPS rats by attenuating pathological angiogenesis in the liver and lungs, showing promise as a treatment for HPS.

show abstract

Section: Discussionmentioning

confidence: 99%